2015 Accounts
|
|
|
| |
|
|
| Acknowledgement of Financial Support (1) |
| |
|
% of total income |
| EPF wishes to thank the European Commission for its support in 2015 in relation to EPF's role in the following projects: |
|
|
| Adapt Smart |
11,693.07 € |
0.6% |
| JA CHRODIS |
19,600.00 € |
1.1% |
| JA PASQ |
18,680.02 € |
1.0% |
| SmartCare |
6,551.93 € |
0.4% |
| PISCE Self Care Tender |
21,601.06 € |
1.2% |
| We Care |
18,934.51 € |
1.0% |
| |
|
|
EPF wishes to thank the following donors for their support:
|
| |
|
|
| Operational work programme |
|
|
| European Commission (Executive Agency for Health and Consumers) |
728,212.00 € |
39.1% |
| Almirall |
20,000.00 € |
1.1% |
| Baxter |
10,000.00 € |
0.5% |
| Gilead |
20,000.00 € |
1.1% |
| GSK |
30,000.00 € |
1.6% |
| MSD |
16,100.00 € |
0.9% |
| Pfizer |
20,000.00 € |
1.1% |
| F.Hoffmann-La Roche |
15,000.00 € |
0.8% |
| Sanofi Pasteur MSD |
20,000.00 € |
1.1% |
| TEVA |
20,000.00 € |
1.1% |
| Membership |
11,000.00 € |
0.6% |
| |
|
|
Capacity building programme
|
|
| Biogen IDEC International GmbH |
20,000.00 € |
1.1% |
| GSK |
30,000.00 € |
1.6% |
| Janssen |
30,000.00 € |
1.6% |
| Lilly |
15,000.00 € |
0.8% |
| Novartis |
35,000.00 € |
1.9% |
| Philips |
25,000.00 € |
1.3% |
| Sandoz |
10,000.00 € |
0.5% |
| |
|
|
The European Patients' Academy on Therapeutic Innovation Public Private Partnership (EUPATI)
|
|
|
| Innovative Medicine Initiative (IMI JU) contribution |
262,397.62 € |
14.1% |
| Industry consortium (Hoffman La Roche, Genzyme, Boehringer, VFA, GSK, AMGEN, ESTVE, Novonordis, S.A. Eli Lilly, Novartis, Astra Zeneca, Bayer, UCB, CHIESI, Janssen, Merck) |
60,856.11 € |
3.3% |
| |
|
|
Project Portfolio
|
|
|
| Abbvie |
25,000.00 € |
1.3% |
| Amgen |
35,000.00 € |
1.9% |
| CSL Behring |
10,000.00 € |
0.5% |
| Grünenthal |
10,000.00 € |
0.5% |
| Hospira Benelux BVBA |
25,000.00 € |
1.3% |
| MSD |
13,900.00 € |
0.7% |
| Sanofi-Aventis |
40,000.00 € |
2.1% |
| Servier |
10,000.00 € |
0.5% |
| Shire |
5,000.00 € |
0.3% |
| |
|
|
Empowerment Campaign
|
|
|
| Amgen |
15,000.00 € |
0.8% |
| Bosch Foundation |
125,000.00 € |
6.7% |
| GSK |
30,000.00 € |
1.6% |
| |
|
|
| |
|
|
Memberships and other income
|
22,202.73 € |
1.2% |
| |
|
|
| Total income |
1,861,728.65 € |
100.0% |
| |
|
|
| Accruals and deferrals (1) |
89,475.84 € |
|
| |
|
|
| Total income net of adjustments |
1,951,204.49 € |
|
| |
|
|
| (1) In accordance with generally accepted accounting principles, funding received in-year is subject to accrual and deferral adjustments proportionate to the level of resources assigned to pluriannual activities and projects. In 2015, this method had the effect of an increase of total income by € 89.475,84 |
| |
|
|
